RxDoctor Payments Data

Keith Warren, MD

Ophthalmology · Overland Park, KSNPI 1790757631

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,375 of the $4,120 with a category attached, or 81.9%. 7 manufacturers reported payments, led by AbbVie at 48.4% of the total. Reporting peaked in 2020 at $1,875 and has fallen 99.2% since, to $14 in 2025.

$4,120in general payments, 2019–2025

Across 14 payments — averaging $294.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Dutch Ophthalmic, USA$212
  • Genentech USA, Inc.$164
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$130
  • Bausch & Lomb Americas Inc.$105
  • plus $14 from 1 others

What the payments were for

  • Consulting fees$3,37582%
  • Food & beverage$74518%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,120 in reported general payments places this provider in the 80th percentile of 135 ophthalmology providers in Kansas.

See all ophthalmology providers in Kansas

Medicare billing

Part B allowed, 2024
$835,328
Medicare patients
671
Services billed
6,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IlevroNepafenac39$14,275
LumiganBimatoprost13$6,166
Latanoprost256$4,619
Tobradex StTobramycin/Dexamethasone18$4,125
Tobramycin-DexamethasoneTobramycin/Dexamethasone47$3,218
Dorzolamide Hcl143$2,951
Prednisolone Acetate32$1,433
Timolol Maleate147$1,422
Atropine Sulfate12$664
Ketorolac Tromethamine17$319
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$213
Diclofenac Sodium19$166
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha24$163
Brimonidine Tartrate17$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$1,995$6,16613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 135 ophthalmology providers in Kansas.

Other ophthalmology in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →